Pfizer Seeks FDA’s OK for Kidney Cancer Drug

Pfizer Inc. said it had asked U.S. regulators for permission to sell its experimental pill against cancers of the kidney and stomach, a product it is counting on to help restore earnings growth.

Pfizer said it had asked the Food and Drug Administration to approve its Sutent pill to treat gastrointestinal stromal tumors, a type of stomach cancer, and kidney cancer that has spread to other parts of the body and has not been controlled by standard treatments.

Shares of Pfizer fell 12 cents to $26.39.